Dabigatran users face increased risks for myocardial infarction and acute coronary syndrome (ACS) relative to those on control medications or placebo, according to a meta-analysis in the Archives of Internal Medicine.
revista
Commentators call the results "robust" and "alarming."
A separate editorial note says the findings "deserve serious consideration" when deciding whether to use dabigatran.
editorial
No hay comentarios:
Publicar un comentario
Danos tu opinion, enriquece el post.